Illumina Inc saw a notable gain as investors responded positively to recent market developments.
Illumina Inc (NASDAQ:ILMN) experienced a significant rise in its stock price, climbing 3.20% in yesterday's session. The company's market cap now stands at approximately $38.56 billion, reflecting growing investor confidence in its innovative genomic technologies.
Advertisement
Illumina Inc
ILMN.US
ILMN.US
Illumina Inc
WealthAwesomeMarket cap
$38.56B
P/E
46.1x
52W high
$256.17
52W low
$88.00
1W change
+11.55%
Beta
1.47
Analyst Price Targets
Based on 20 analysts covering ILMN · as of Sep 17, 2026
Wall Street analysts forecast ILMN stock price to fall 20.6% over the next 12 months.
Consensus
Buy3.75 / 5.00
Avg. Target
C$202.65
-20.6% Upside
Current Price
C$255.38
Last close
Analyst Breakdown (20 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ILMN's historical volatility
30-Day Vol
51.6%
Annualized
90-Day Vol
45.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$305.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$271.04 | C$226.85 – C$323.84 |
| 60 trading days | C$287.67 | C$223.65 – C$370.00 |
| 90 trading days | C$305.31 | C$224.31 – C$415.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The increase in Illumina's stock price indicates a renewed optimism among investors, driven by the company's strategic advancements in genomic sequencing and its role in the booming healthcare sector.
Illumina's stock price closed at CA$255.38 yesterday.
The stock's 3.20% increase reflects a broader trend of investor interest in healthcare stocks, which have outperformed the S&P 500 significantly over the past six months.
Bull case
Illumina is a leader in genomic sequencing technology, which positions it well to take advantage of the growing market for genetic testing, especially in neonatal care and oncology. The company's recent initiatives and partnerships are boosting its growth potential.
Bear case
Despite the positive movement, analysts are concerned about Illumina's organic revenue growth, which has not met expectations. Additionally, insider selling may indicate potential volatility ahead.
Advertisement
Market Reaction to Illumina's Innovations
Illumina's recent advancements in genomic sequencing technology have captured investor attention. The company's innovative solutions are increasingly seen as essential in the rapidly growing field of personalized medicine, particularly in oncology and neonatal care. This has led to a surge in demand for its products, contributing to the positive stock performance.
Concerns Amidst the Gains
While the stock's rise is encouraging, analysts caution that Illumina's organic revenue growth has fallen short of expectations. This raises questions about the sustainability of its growth trajectory. Additionally, significant insider selling may signal potential risks for investors, suggesting that caution may be warranted despite the recent gains.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
